Back to School: How biopharma can reboot drug development. Access exclusive analysis here

StarGen: Phase I/IIa suspended enrollment

Oxford BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat after detecting "very low" concentrations of potential impurities in clinical trial material. The company believes the impurities are

Read the full 372 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE